Details

Project TitleCell Lines for High Throughput Screening of Estrogenic Compounds
Track CodeP150257US01
Websitehttp://www.warf.org/technologies/summary/P150257US01.cmsx
Short DescriptionTwo estrogen receptor isoforms regulate normal mammary cells in response to estrogen: ERα and ERβ. ERα is currently a therapeutic target in breast cancer, and breast cancers expressing ERα are commonly treated with ERα antagonists including tamoxifen and raloxifene. It is estimated that 50 to 60 percent of triple negative breast cancers express ERβ and it may also prove to be an effective therapeutic target.

A UW–Madison researcher has developed cells lines, Hs578T-ERαLuc and Hs578T-ERβLuc, with stable estrogen receptor elements fused to luciferase genes as well as separate inducible estrogen receptor (ER) constructs. Inducible ER expression will allow the use of high throughput screening for identifying ER-selective ligands inside cells.
AbstractThe Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing cell lines for screening and characterization of the estrogen receptor specificity of compounds.
 
Tagsbiotechnology, Cell Line, estrogen receptor, breast cancer
 
Posted DateJul 26, 2017 9:22 PM

Advantages

  • Biomaterial readily available for licensing
  • Valuable tools for identifying compounds that show selectivity for ERα and ERβ given their sensitivity, selectivity and stability

Potential Applications

  • These cell lines provide a high throughput format to screen for compounds that selectively activate either ERα or ERβ.

Additional Information

Contact Information

TTO Home Page: http://www.warf.org



Name : Jennifer Gottwald

Title : Director of Licensing

Department : Licensing

Email : jennifer@warf.org

Phone : 608-960-9854

Address : 614 Walnut Street, 13th floor, Madison, WI 53726

Principal Investigator

Name : Frank Secreto

Department : Mayo Foundation for Medical Education and Research



Name : John Hawse

Department : Mayo Foundation for Medical Education and Research



Name : Wei Xu

Department : Oncology

Intellectual Property